⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iv colorectal cancer ajcc v7

Every month we try and update this database with for stage iv colorectal cancer ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal TumorsNCT02757391
Colorectal Aden...
Metastatic Chol...
Metastatic Colo...
Metastatic Dige...
Metastatic Esop...
Metastatic Gast...
Metastatic Panc...
Stage IV Colore...
Stage IV Esopha...
Stage IV Gastri...
Stage IV Pancre...
Stage IVA Color...
Stage IVB Color...
Adoptive Immuno...
Aldesleukin
Cyclophosphamid...
Laboratory Biom...
Pembrolizumab
18 Years - M.D. Anderson Cancer Center
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerNCT02888743
Metastatic Colo...
Metastatic Lung...
Stage IV Colore...
Stage IV Lung N...
Stage IVA Color...
Stage IVB Color...
Durvalumab
Radiation Thera...
Tremelimumab
18 Years - National Cancer Institute (NCI)
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by SurgeryNCT02292758
Colorectal Aden...
RAS Wild Type
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Bevacizumab
Cetuximab
Irinotecan
Laboratory Biom...
Placebo
18 Years - Academic and Community Cancer Research United
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by SurgeryNCT02738606
Metastatic Colo...
Metastatic Mali...
Metastatic Mali...
Recurrent Color...
Resectable Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Chemotherapy
Laboratory Biom...
Metastasectomy
Quality-of-Life...
Therapeutic Con...
18 Years - M.D. Anderson Cancer Center
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal CancerNCT02368886
Colon Adenocarc...
Rectal Adenocar...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Clobetasol Prop...
Pharmacological...
Quality-of-Life...
Regorafenib
18 Years - Academic and Community Cancer Research United
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT StudyNCT02997228
Metastatic Colo...
Stage IV Colore...
Atezolizumab
Bevacizumab
Biospecimen Col...
Computed Tomogr...
Fluorouracil
Leucovorin
Magnetic Resona...
Oxaliplatin
Positron Emissi...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI)
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerNCT02600949
Metastatic Colo...
Metastatic Panc...
Stage IV Colore...
Stage IV Pancre...
Stage IVA Color...
Stage IVB Color...
Imiquimod
Pembrolizumab
Sotigalimab
Synthetic Tumor...
Computed Tomogr...
Magnetic Resona...
18 Years - M.D. Anderson Cancer Center
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryNCT01787500
BRAF NP_004324....
KRAS wt Allele
Metastatic Mali...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Unresectable So...
Cetuximab
Irinotecan Hydr...
Laboratory Biom...
Pharmacological...
Vemurafenib
18 Years - M.D. Anderson Cancer Center
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus PanitumumabNCT03300609
Colorectal Aden...
RAS Wild Type
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Panitumumab
Oxaliplatin
Leucovorin Calc...
Fluorouracil
Capecitabine
Quality-of-Life...
Laboratory Biom...
18 Years - University of Southern California
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerNCT02888743
Metastatic Colo...
Metastatic Lung...
Stage IV Colore...
Stage IV Lung N...
Stage IVA Color...
Stage IVB Color...
Durvalumab
Radiation Thera...
Tremelimumab
18 Years - National Cancer Institute (NCI)
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal CancerNCT02368886
Colon Adenocarc...
Rectal Adenocar...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Clobetasol Prop...
Pharmacological...
Quality-of-Life...
Regorafenib
18 Years - Academic and Community Cancer Research United
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by SurgeryNCT02738606
Metastatic Colo...
Metastatic Mali...
Metastatic Mali...
Recurrent Color...
Resectable Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Chemotherapy
Laboratory Biom...
Metastasectomy
Quality-of-Life...
Therapeutic Con...
18 Years - M.D. Anderson Cancer Center
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by SurgeryNCT02754856
Metastatic Carc...
Resectable Mass
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Durvalumab
Laboratory Biom...
Therapeutic Con...
Tremelimumab
18 Years - M.D. Anderson Cancer Center
Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by SurgeryNCT03396926
Microsatellite ...
Mismatch Repair...
Stage III Color...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Bevacizumab
Capecitabine
Laboratory Biom...
Pembrolizumab
18 Years - University of California, San Francisco
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerNCT02600949
Metastatic Colo...
Metastatic Panc...
Stage IV Colore...
Stage IV Pancre...
Stage IVA Color...
Stage IVB Color...
Imiquimod
Pembrolizumab
Sotigalimab
Synthetic Tumor...
Computed Tomogr...
Magnetic Resona...
18 Years - M.D. Anderson Cancer Center
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal CancerNCT03087071
EGFR NP_005219....
KRAS Gene Mutat...
MAP2K1 Gene Mut...
Metastatic Colo...
Refractory Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Laboratory Biom...
Panitumumab
Trametinib
18 Years - M.D. Anderson Cancer Center
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT StudyNCT02997228
Metastatic Colo...
Stage IV Colore...
Atezolizumab
Bevacizumab
Biospecimen Col...
Computed Tomogr...
Fluorouracil
Leucovorin
Magnetic Resona...
Oxaliplatin
Positron Emissi...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI)
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal CancerNCT03087071
EGFR NP_005219....
KRAS Gene Mutat...
MAP2K1 Gene Mut...
Metastatic Colo...
Refractory Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Laboratory Biom...
Panitumumab
Trametinib
18 Years - M.D. Anderson Cancer Center
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069
Acute Lymphobla...
Acute Myeloid L...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Chronic Lymphoc...
Chronic Myeloid...
Gastroesophagea...
Head and Neck C...
Hematopoietic a...
Invasive Breast...
Kidney Carcinom...
Malignant Hepat...
Malignant Solid...
Melanoma
Muscle-Invasive...
RISS Stage I Pl...
RISS Stage II P...
RISS Stage III ...
Sarcoma
Stage I Bladder...
Stage I Breast ...
Stage I Colorec...
Stage I Esophag...
Stage I Gastric...
Stage I Lung Ca...
Stage I Ovarian...
Stage I Pancrea...
Stage I Prostat...
Stage I Uterine...
Stage II Bladde...
Stage II Breast...
Stage II Colore...
Stage II Esopha...
Stage II Gastri...
Stage II Lung C...
Stage II Ovaria...
Stage II Pancre...
Stage II Prosta...
Stage II Uterin...
Stage III Bladd...
Stage III Breas...
Stage III Color...
Stage III Esoph...
Stage III Gastr...
Stage III Lung ...
Stage III Ovari...
Stage III Pancr...
Stage III Prost...
Stage III Uteri...
Stage IV Bladde...
Stage IV Breast...
Stage IV Colore...
Stage IV Esopha...
Stage IV Gastri...
Stage IV Lung C...
Stage IV Ovaria...
Stage IV Pancre...
Stage IV Prosta...
Stage IV Uterin...
Thyroid Gland C...
Questionnaire A...
Biospecimen Col...
40 Years - 75 YearsAlliance for Clinical Trials in Oncology
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by SurgeryNCT02292758
Colorectal Aden...
RAS Wild Type
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Bevacizumab
Cetuximab
Irinotecan
Laboratory Biom...
Placebo
18 Years - Academic and Community Cancer Research United
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: